Solid Biosciences Inc
SLDB6.684USD
-0.146-2.14%
交易中 （美東）報價延遲15分鐘
517.94M總市值
虧損本益比TTM
關於 Solid Biosciences Inc 公司
Solid Biosciences Inc. 是一家生命科學公司，致力於開發用於神經肌肉和心臟疾病的精準基因藥物。該公司專注於推進一系列基因治療候選藥物，包括用於治療杜氏肌營養不良症的 SGT-003、用於治療兒茶酚胺能多形性室性心動過速的 SGT-501、用於治療 BAG3 介導的擴張型心肌病的 AVB-401，以及用於治療致命心臟疾病的其他資產。該公司還有兩個心臟管線基因轉移項目，用於 TNNT2 DCM 的 SGT-601 和用於 RBM20 DCM 的 SGT-701，均處於早期臨牀前開發階段。它還有一個用於治療弗裏德賴希共濟失調的神經肌肉基因轉移項目。除了基因轉移候選藥物外，該公司還有專注於平臺技術的開發項目，包括新型衣殼庫和雙基因表達，雙基因表達是一種允許將多個轉基因包裝到一個衣殼中的技術。
公司簡介
公司代碼SLDB
公司名稱Solid Biosciences Inc
上市日期Jan 26, 2018
CEOMr. Alexander (Bo) Cumbo
員工數量100
證券類型Ordinary Share
年結日Jan 26
公司地址500 Rutherford Avenue
城市CHARLESTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02129
電話16173374680
網址https://www.solidbio.com/
公司代碼SLDB
上市日期Jan 26, 2018
CEOMr. Alexander (Bo) Cumbo
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
13.23K
+51.52%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
收入明細
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
股東類型
持股股東
佔比
Investment Advisor
32.52%
Hedge Fund
31.63%
Private Equity
15.36%
Investment Advisor/Hedge Fund
13.19%
Venture Capital
8.97%
Research Firm
0.87%
Individual Investor
0.56%
Bank and Trust
0.04%
Family Office
0.01%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
235
79.94M
103.13%
+26.28M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
2023Q1
234
16.00M
82.14%
-1.37M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
11.91M
15.36%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.21%
+2.88M
+57.15%
Mar 31, 2025
Invus Public Equities Advisors, LLC
7.42M
9.57%
+3.67M
+97.81%
Mar 31, 2025
Adage Capital Management, L.P.
6.73M
8.68%
+4.98M
+284.96%
Mar 31, 2025
Commodore Capital LP
5.83M
7.51%
--
--
Mar 31, 2025
RA Capital Management, LP
4.33M
5.59%
+90.74K
+2.14%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.52M
4.54%
+3.47M
+7432.14%
Mar 31, 2025
VR Adviser, LLC
2.48M
3.2%
+2.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.46M
3.17%
+1.06M
+75.59%
Mar 31, 2025
Redmile Group, LLC
2.02M
2.6%
+1.40M
+228.19%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
0.67%
Tema Neuroscience and Mental Health ETF
0.29%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
查看更多
iShares Neuroscience and Healthcare ETF
佔比0.67%
Tema Neuroscience and Mental Health ETF
佔比0.29%
iShares Micro-Cap ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
公告日期
類型
比率
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
